Clinical aspects and therapy of gastrointestinal MALT lymphoma
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 30 (1-2) , 109-117
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Second Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and Followed for 10 YearsGastroenterology, 2012
- Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral TherapyJournal of Immunology Research, 2012
- Genomic profiles of MALT lymphomas: variability across anatomical sitesHaematologica, 2011
- A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non‐Hodgkin lymphoma riskBritish Journal of Haematology, 2011
- A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasBritish Journal of Haematology, 2009
- The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomasBlood, 2009
- Chlorambucil versus observation after anti‐Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trialBritish Journal of Haematology, 2009
- Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide studyEuropean Journal of Cancer, 2008
- Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori TherapyJournal of Clinical Oncology, 2005
- Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003